Avstera Therapeutics

AVS200 RD oncology; AVS300 RD solid tumors

Avstera Therapeutics is developing innovative therapies for oncology. Avstera leverages cutting-edge approaches to tackle key immunological challenges seen in the tumor microenvironment, such as the modulation of immunosuppressive macrophages. Their pipeline includes a promising oral HDAC6 inhibitor, AVS100, which has demonstrated significant preclinical efficacy in targeting solid tumors, a myeloid cell therapy platform (AVS200), and mRNA cancer vaccine encoding TEM1 (AVS300). AVS100 is currently in clinical development, with ongoing Phase I trials evaluating its safety and efficacy for the treatment of locally advanced or metastatic solid tumors. Avstera's commitment to developing innovative therapies for cancer patients positions them as a promising player in the oncology field.

Jobs: